Search Results for: covid-19
Articles
POP Biotechnologies Vaccine Technology to Enter Phase 3 Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19 February 7, 2022
POP Biotechnologies recently announced the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine...Theralase Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine February 7, 2022
Theralase Technologies Inc. has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 (COVID-19) vaccine…..
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome January 31, 2022
Veru Inc. recently announced the US FDA has granted Fast Track designation to the Phase 3 registration program for the...Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program January 27, 2022
Cocrystal Pharma, Inc. has selected two investigational novel antiviral drug candidates for further development as oral treatments for SARS-CoV-2, the virus that causes COVID-19…..
TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19 January 27, 2022
TFF Pharmaceuticals, Inc. recently announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial (CT.gov...SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19 January 24, 2022
SAB Biotherapeutics recently reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required for advancement...Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 January 19, 2022
Revive Therapeutics Ltd. recently provided an update on the company’s US FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with….
Resverlogix Announces Commencement of Patient Enrollment & Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment January 18, 2022
Resverlogix Corp. recently announced enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone….
UAB & Mereo Announce Positive Top-line Results From Phase 1b/2 Trial of Alvelestat in Hospitalized Patients With COVID-19 Respiratory Disease December 22, 2021
The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc recently announced top-line data from a Phase 1b/2...Cocrystal Pharma’s COVID-19 Oral & Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant December 22, 2021
Cocrystal Pharma, Inc. recently announced in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant…..
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine December 20, 2021
Novavax, Inc. recently announced the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for Novavax' COVID-19 vaccine...Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron December 16, 2021
Vaxart, Inc. recently announced it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron...ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized With COVID-19 December 2, 2021
ARCA biopharma, Inc. recently announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a...Sterling Pharma Solutions Announces Exclusive Partnership to Develop Novel Route to Newly Approved COVID-19 Therapy December 1, 2021
Sterling Pharma Solutions recently announced an exclusive partnership with the University of Manchester Institute of Biotechnology (MIB), to support the development of a novel, low-cost manufacturing route to molnupiravir, a new….
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial December 1, 2021
Arch Biopartners Inc. recently announced its lead drug candidate, LSALT Peptide (LSALT and Metablok) will enter the Canadian Treatments for...ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing & Manufacturing Next-Generation COVID-19 Vaccines November 18, 2021
ImmunityBio, Inc. recently announced the expansion of the company’s cancer and infectious disease vaccine programs to include self-amplifying self-adjuvating RNA (SASA-RNA), recombinant protein vaccine candidates, and potent adjuvant formulations that….
Vaxart Announces Publication of Complete Data From Preclinical COVID-19 Oral Vaccine Hamster Challenge Study November 16, 2021
Vaxart, Inc. recently announced the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study. The...Emergex Announces Approval to initiate Phase 1 Clinical Trial of Its Next-Generation COVID-19 Vaccine Candidate November 15, 2021
Emergex Vaccines Holding Limited recently announced it has received the necessary regulatory approvals to initiate a Phase 1 clinical trial...CN Bio & iiCON Announce COVID-19 Research Collaboration November 9, 2021
CN Bio recently announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D program,...Novavax & Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia November 1, 2021
Novavax, Inc. and Serum Institute of India Pvt. Ltd. (SII) recently announced that the National Agency of Drug and Food...
